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Chemical compounds studied in this article:
DiR (PubChem CID 25195411)
DiI (PubChem CID 5706736)Nanoparticle-based drug delivery to ease anticancer therapy relies primarily on the enhanced permeability and
retention effect (EPR). The leaky vascular structure in tumors allows extravasation of nanoparticles, often termed
passive targeting. Long term retention of nanoparticles is attributed to the lack of lymphatic drainage, and unidi-
rectional extravasation has been implied.
Fluorescent liposomes with a plasma half-life of 29 h were injected into tumor-bearing rats, and biodistribution
in tumor, skin, paws and earswasmonitored via in vivo ﬂuorescencemeasurements. To calculate tissue accumu-
lation, an algorithmwas developed to subtract the blood signal from the total ﬂuorescence recorded. Accumula-
tion in tumor tissue was much higher than that in other tissues monitored, initially exhibiting very rapid
accumulation followed by a long plateau phasewith little change. Discontinuous plasmapheresis was established
that was as effective as highly sophisticated clinical plasmapheresis. We observed no difference in the tumor
tissue's accumulation when plasmapheresis was performed 22 h after liposome injection. In contrast, plasma-
pheresis led to a signiﬁcant inhibition of further accumulation in other tissues. When the liposomes' blood con-
centration was rapidly lowered, we detected no drop in tumor ﬂuorescence. Thus extravasation via EPR is most
likely a route of no return. These data support the emerging view of amore dynamicmodel of EPR,where gaps or
entire vessels may open and close over time, or accumulated liposomes become entangled within the pores,
hampering further accumulation.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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In vivo imaging1. Introduction
The Enhanced Permeability and Retention effect (EPR) was ﬁrst de-
scribed in 1986 by Maeda et al. [1,2] and has attracted great interest in
conjunction with the further development of nanomedicine in the last
several years [3,4]. The rapid and irregular angiogenesis in spreading
tumor tissues leads to a widespread fenestration of blood vessels and
impaired vessel structure in the neovasculature of tumor tissues. In con-
trast to healthy endothelial layers, nanoparticles can easily extravasate
into the tumor's interstitium through its leaky vasculature [5]. Such en-
hanced permeation leads tomuch higher accumulation of nanoparticles
in tumor tissues than in other organs. Today, much is known about un-
even distribution [6] and particle size dependency [7], but certain obsta-
cles remain. The accumulation of nanoparticles in tumor tissue by EPRal Center, Institute for Clinical
e (R. Ngoune),
dt),
.puetz@uniklinik-freiburg.de
. This is an open access article underhas been shown to be much faster than in other tissues. While tissues
like the skin continue to accumulate liposomes, accumulation in
tumor is somehow hampered after several hours [8]. This effect cannot
be attributed to a saturation effect, since the maximum accumulation
correlated closely with the initial plasma concentration [8,9]. Accumu-
lated particles remain inside the tumor for a long time, one prerequisite
being the lack of lymphatic drainage [1,10]. Liposomes are eliminated in
plasma much faster than in tumor [8,11,12]. Thus accumulation should
contain an irreversible step, so that accumulated liposomes cannot dif-
fuse back into the bloodstream. Pegylated liposomes do not readily in-
teract with tumor cells and are retained in the tumor stroma [13],
thus interaction with cells like endocytosis is probably not responsible
for liposome retention. Extravasation of macromolecules and particles
from blood to tumor may be a pathway of no return [11,14].
Plasmapheresis is an extracorporeal process by which toxic compo-
nents, e.g., excess lipids, are removed from the blood. Selective plasma-
pheresis is a well-established therapeutic method nowadays to treat
many different diseases [15]. Double ﬁltration plasmapheresis (DFPP),
originally designed to eliminate low density lipoproteins (LDL), is
known to eliminate nanoparticles like liposomes as well [16]. During
DFPP, cellular components and plasma are separated in an initial ﬁltra-
tion step. Separated plasmapasses through a secondﬁlter to remove the
respective particles or proteins. Filtered plasma is reunited with thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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fashion. Scheduled plasmapheresis can be used to diminish the side ef-
fects of pegylated liposomal doxorubicin in a clinical setting [17].
There is currently little data on detailed accumulation kinetics in
mousemodels [12,18,19], andmost rely on few data points because an-
imals had to be sacriﬁced for each measurement. In vivo ﬂuorescence
measurements in small animal models allow visualisation of tumor ac-
cumulation [20] and provide a new opportunity for detailed and contin-
uous follow-up of accumulating liposomes in tumor and other tissues
within the same animal over time, provided that the ﬂuorescent dye is
ﬁrmly associated with the liposomes [19].
In the present study, we investigated the detailed biodistribution of
pegylated liposomes in tumor, skin, paws and ears via in vivo ﬂuores-
cence imaging in a syngeneic rat tumor model. Plasmapheresis in
small animals was established to rapidly lower the liposomal plasma
concentration. We discuss the changes in biodistribution observed,
their implications for understanding the EPR-effect as well as possible
clinical implications.
2. Experimental methods
2.1. Materials
HSPC (hydrogenated soybean phosphatidylcholine) was purchased
from Avanti Polar Lipids (Alabaster, USA). DSPE-PEG2000 (2-
distearoyl-sn-glycero-3 phosphoethanol-amine-N-[methoxy (polyeth-
ylene glycol)-2000]) was provided by Corden Pharma (Liestal,
Switzerland). Cholesterol and phosphate buffered saline (PBS) was pur-
chased from Sigma-Aldrich® (Steinheim, Germany). DiO (3,3′-
dioctadecyloxacarbocyanine perchlorate), DiI (1,1′-dioctadecyl-
3,3,3′,3′-tetramethylindocarbocyanine perchlorate) and DiR (1,1′-
dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide) was pur-
chased from Invitrogen Molecular Probes (Karlsruhe, Germany). Lipid
ﬁlters (10 mm diameter × 60 mm length) were custom made by
Membrana GmbH (Wuppertal, Germany), containing polyethersulfone
hollow ﬁbers FraktioPES® 40/200 (inner surface area 5.8 cm2), having
sieving coefﬁcients of 0.75 for human serum albumin and IgG, 0.88 for
human high density lipoprotein (HDL) and 0.17 for IgM. Liposomes
were retained completely.
2.2. Preparation and characterization of liposomes
Liposomes were prepared by extrusion [21] and consisted of HSPC/
cholesterol/DSPE-PEG2000/DiR in the molar ratio 50/39/10/1. For ﬂuo-
rescence microscopy and plasma concentration measurements, DiI
was added in the same concentration as DiR. Brieﬂy, all lipids were dis-
solved in chloroform and mixed, the chloroform was then removed
with a rotation evaporator and lipids were dried in vacuum. The dry
lipid ﬁlm was hydrated with a HEPES buffer (118 mM NaCl, 4.74 mM
KCl, 1.2 mM MgCl2, 0.59 mM KH2PO4, 0.59 mM Na2HPO4, 10 m M
HEPES, pH 7.4) at 50 °C by rotation. The generated lipid suspension
was extruded ﬁrst through a 200 nm and later through a 100 nm diam-
eter membrane to obtain liposomes.
Liposomes were characterized by photon correlation spectroscopy
(Nicomp Submicrom Particle Analyser Model 380) to determine their
mean size, size distribution, and polydispersion index (PDI). HSPC con-
centration was quantiﬁed according to Stewart [22].
2.3. Cell culture
MAT-B-III Cells (ATCC® CRL-1666™, American Type Culture Collec-
tion, Manassas, USA) were cultured in Iscove basal medium (Biochrom,
Berlin, Germany) supplemented with 10% Fetal Calf Serum (Biochrom)
at 37 °C in a humidiﬁed incubator with 5% CO2 atmosphere. The medi-
um was replaced every 6 days, and the cells seeded into a new culture
dish when a conﬂuence of 80% was attained.2.4. Animals
Female Fischer's rats F344/DuCrl (160–200 g) were purchased from
Charles River (Sulzfeld, Germany). Animal experiments were per-
formed according to regional and national guidelines and approved by
the local authority. The rats were fed ad libitum, the temperature and
relative humidity were kept constant at 20–21 °C and 60%, respectively.
All animals were euthanized at the end of experiments.
Syngenic MAT-B-III rat mammary tumor cells were trypsinized and
resuspended in PBS. To generate tumors, a total of 2 ∗ 105 cells in
100 μl PBS were inoculated subcutaneously in the ﬂank of female Fi-
scher rats. The studies were started 10–14 days after cell inoculation
when tumors had reached a size of ~0.5–1 cm3. A total of 10 animals
were assigned to the control and plasmapheresis group each. One ani-
mal died in the plasmapheresis group and 1 animal pair was excluded
because due to a technical mishap, they had undergone plasmapheresis
much later than the other animals had, leaving 9 animals in the control
group and 8 in the plasmapheresis group.
2.5. Gel permeation chromatography
The gel permeation chromatography (GPC) system BioLogic
DuoFlow (BIORAD, München, Germany) equipped with a Tricorn® col-
umn (10 mm diameter, 600 mm length) was loaded with Superose 6
prep grade (both from GE Healthcare, Freiburg, Germany). The running
buffer consisted of PBS, sodium acid (200 mg/l) and EDTA (372.3 mg/l).
Prior to application, 40 μl of the samples were diluted with 260 μl of
buffer and applied to the column. Separations were performed at a
ﬂow rate of 0.2 ml/min, collected volume was 1 ml each fraction. The
UV detector measured the optical density of the eluate at 280 nm. The
equipment was washed and regenerated with running buffer after
each run.
2.6. Measurement of ﬂuorescence in plasma probes
To a volume of 10 μl of plasma probes containing liposomes, 90 μl of
H2Owere added. Toprecipitate proteins, 10 μl of 3M trichloroacetic acid
were added to the mixture. Samples were centrifuged and the ﬂuores-
cence measured using a ﬂuorometer type LS 50 (Perkin Elmer, Rodgau,
Germany).
2.7. Fluorescence imaging
In vivo ﬂuorescence imaging was performed with an IVIS® Spec-
trum imaging system (Perkin Elmer) at different times after intravenous
injection of dye-labeled liposome to an end concentration of 4mM lipo-
somal lipids in plasma. Images were acquired using an excitation and
emission wavelength of 750/780 nm. Identical illumination settings,
i.e., exposure time (2 s), f/stop (auto), binning factor (small (hi resolu-
tion)) and ﬁeld of view (25 × 25 cm) were used. Imaging data analysis
was performed with Living Image® 4.1 software (Perkin Elmer, USA).
Quantitative data was obtained by choosing respective regions of inter-
est (ROI). A diameter of 15 mmwas selected for the ROIs of tumor and
skin. For ears and paws, ROI diameters of 5 mmwere chosen. Quantita-
tive ﬂuorescence data were based on total radiant efﬁciency (TRE), ac-
counting for the sum of all signals in respective ROIs. Intensities were
measured as [(p/s/cm2/sr)/(μW/cm2)] and are given as arbitrary units
throughout the paper to facilitate legibility. To account for differences
in individual liposomal preparations and variances in individual mea-
surements, marker concentrations of respective liposomal preparations
were used to normalize measured TRE (panel on top left side in Fig. 3).
TRE for skin, paw and ear were recorded directly. Since tumors were
growing subcutaneously, the tumor signalwas calculated by subtracting
the respective signal for skin from recorded TRE in the tumor region.
During imaging, the animals were sedated with isoﬂurane gas
anesthetic.
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Recorded TREwere composed of tissue autoﬂuorescence, liposomes
in the blood ﬂoating through tissue vessels and liposomes that have ac-
cumulated in the tissue. Background ﬂuorescencewas recorded prior to
liposomal injection and subtracted from the recorded TRE. To account
for the respective signal derived from accumulated liposomes (Ftissue),
the signal of liposomes derived from blood (Fblood) had to be subtracted
from measured TRE. Assuming that accumulation is slow, the ﬁrst TRE
obtained after 15–30 min was counted as the initial blood signal
(Fblood(0)). The blood signal's decay over time was calculated using
the measured liposomal half-life and ﬁrst order kinetics.
Fblood tð Þ ¼ Fblood 0ð Þ exp −
t
41:5
 
Respective tissue accumulation was then calculated by subtracting
the calculated blood signal from measured TRE for each time point.
Ftissue tð Þ ¼ TRE tð Þ−Fblood tð Þ−Fbackground
Calculationswere done in the plasmapheresis group as in the control
group until plasmapheresis (t = 22 h) was initiated. Assuming that
plasmapheresis only eliminates liposomes from the blood, the mea-
sured difference between TRE(22 h) and TRE(24 h)was then subtracted
from the calculated Fblood(22 h) to yield Fblood(24 h). Further decay of
blood ﬂuorescence was then calculated starting with Fblood(24 h) as de-
scribed above.
Tissue ﬂuorescence time curves were ﬁtted to a fast exponential ac-
cumulation term and a slow linear decay when appropriate:
Ftissue tð Þ ¼ Amaxð1− exp −
t
k1
2
 !
−Dt
with Amax the theoretical maximum accumulation and D the elimina-
tion constant.
Accumulation half-time can be calculated by:
A1
2
¼ ln 2ð Þk1
2
Images of different animals could not be taken at exactly the same
time points. Thus time frames were deﬁned, and the average ﬂuores-
cence calculated within the corresponding time frame was attributed
to respective averaged recording time (see Supplement 1 and 2 for de-
tailed data). If no measurement existed within the respective time
frame for a single animal, linear extrapolation was done by referring
to the nearest time points measured.
2.9. Discontinuous plasmapheresis
Discontinuous plasmapheresis (DCP) was performed 22 h–24 h
after intravenous injection of liposomes under isoﬂuran anesthesia.
After intravenous injection of heparin through a venous access (BD
Insyte-W 24GA 0.7 ∗ 19 mm), a blood sample of 1.5 ml was taken
from the tail vein with a venipuncture (Venoﬁx A 25G ∗ 0.5 ∗ 15 mm)
set and centrifuged (4500×g; 1min) to separate plasma from the cellu-
lar components. The plasmawas aspired and ﬁltered through a lipid ﬁl-
ter as described above. The ﬁltrate and cellular components were
reunited and returned to the rat via the venous blood access. This step
was repeated up to 7 times. The plasmapheresis took 1 h–1.5 h.
2.10. Tissue ﬂuorescence ex vivo
Fluorescent liposomesmarkedwith DiI andDiRwere given to tumor
bearing rats (4mM liposomal PC in plasma) and 48 h after injection the
animals were sacriﬁced. Liver, spleen, lung, tumors, paws, skin and earswere prepared andﬂorescence intensitiesmeasured as described above.
For each organ, two ROI with a diameter of 0.5 cm were deﬁned. ROI
were placed to reach maximum intensities. Measured intensities were
normalized to marker intensities (4 mM liposomal PC). Both measure-
ments of the same organ were averaged, and these averages were
used to calculate the mean and s.d. of the organ distribution.
2.11. Fluorescence imaging
Aftermeasurement of tissueﬂuorescence as described above, dissec-
tions of respective organs were embedded in tissue freezing medium
(Leica Biosystems Nussloch GmbH, Nussloch, Germany) and frozen to
−80 °C. Tissues were sliced on a microtome CM3050 S (Leica
Biosystems) at −20 °C. Fluorescence microscopy was done with a
Zeiss microscope Observer Z1, equipped with a Colibri ﬂuorescence
unit, excitation wave length was 555 nm, emission ﬁlter was 577-602.
Pictures (20× objective) were taken with the aid of an AxioCam MRC,
and processed by ZEN 2012 (blue edition) software (all Carl Zeiss Mi-
croscopy GmbH, Goettingen, Germany).
2.12. Statistical analysis
Data plots and curve ﬁts were created using Prism® software ver-
sion 6.05 (GraphPad Inc.), which was used for statistical analysis as
well. Normality of data distribution was tested by Shapiro-Wilk criteria,
assumingGaussian distributionwhen p N 0.05. Calculated p-valueswere
classiﬁed into 3 signiﬁcance levels (*** p b 0.01; ** 0.01 b p N 0.05 and *
0.05 b p N 0.1). Fitted equations for the accumulation time-curves were
subjected to the extra-sum-of-squares F test to justify the use of two dif-
ferent ﬁts for the control and plasmapheresis group, instead of a single
ﬁt for both groups (null hypothesis).
3. Results
3.1. Liposomes
Long circulating liposomes were prepared by extrusion technique
with an average diameter of 174 nm (±7 nm), the average PI was
0.051 (±0.016).When 4mM liposomal PC in plasmawere used, the av-
erage T½ was 29 h (95% CI 25–32 h), assuming a ﬁrst order elimination
kinetic (Fig. 1A). As ﬂuorescentmembranemarker, we used the near in-
frared dye DiR tominimize animal backgroundﬂuorescence. To rule out
signiﬁcant exchange of liposomalmarker with other blood components
in vivo, plasmawas fractionated byGPC [23] (Fig. 1B). Liposomes eluted
with very low density lipoproteins (VLDL). We observed no changes in
lipoprotein proﬁle for up to 72 h.When a large amount of liposomes has
been cleared, a certain increase in LDL and HDL fractions was seen at 48
and 72 h. Liposomal lipids are probably metabolized, appearing later in
lipoproteins. Fluorescence was detected only in plasma fractions in ref-
erence to liposomes, while no ﬂuorescence was detected in LDL, HDL or
plasma protein fractions (Fig. 1C). Thus no signiﬁcant exchange of lipo-
somal marker occurs with LDL, HDL or plasma proteins like albumin in
the blood. An exchangewith VLDL cannot be ruled out by chromatogra-
phy, but since VLDL convert rapidly to LDL, ﬂuorescence in VLDL should
appear in LDL later on. Thus the liposomalmarker DiR is stable and well
suited for long term in vivo experiments in the rat when incorporated
into liposomes during preparation.
3.2. Plasmapheresis
Tominimize the strain on animal health and instrumental complex-
ity, we developed a simple and fast DCP technique. For a wash step,
~1.5 ml blood were taken via a tail vein catheter, plasma was separated
by centrifugation and subsequently ﬁltered. Liposomes were retained
within the ﬁlter completely. The efﬁciency of liposome elimination by
DCP is shown in Fig. 2. Up to 59% (±10%) of circulating liposomes in
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Fig. 1. Fluorescent Liposomes in human plasma. Pegylated liposomes prepared with
ﬂuorescent dye DiR (HSPC/Cholesterol/DSPEPEG2000/DiR 39/30/10/1) were injected
into the tail vein of female Fisher rats to yield a blood concentration of ~4 mM liposomal
PC. A) Decay of liposomal ﬂuorescence in plasma (n = 6). Half-life was estimated
assuming ﬁrst order kinetics. B) Gel permeation chromatography of plasma after
injection of liposomes (n = 3). VLDL – very low density lipoprotein, LDL - low density
lipoprotein, HDL – high density lipoprotein. C) Gel permeationchromatography of
plasma after injection of liposomes, ﬂuorescence versus time (n= 3).
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Fig. 2. Elimination of liposomes by discontinuous plasmapheresis. For each wash step
~1.5 ml blood was drawn. Plasma was separated by centrifugation and ﬁltered, then
reunited blood was given back to the animals (n = 7). Theoretical elimination was
calculated according to 10 ml total blood volume and 1.5 ml blood drawn.
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approx. One blood volume of a rat weighing 180–200 g. DCP was as ef-
fective as expected for 1.5 ml blood/step and a total blood volume of
10 ml. Plasmapheresis took 1–1.5 h and was well tolerated by the
animals.
3.3. In vivo ﬂuorescence imaging
We tested different dyes to obtain the best ratio of tissue auto ﬂuo-
rescence to signal intensity. Of the DiO, DiI, and DiR dyes, the near infra-
red dye DiR yielded the lowest tissue auto ﬂuorescence and was chosen
for further experiments (data not shown). Tissue auto ﬂuorescence is
given in Fig. 4. The signal linearity was veriﬁed by different liposomal
concentrations between 0.05 and 4 mM liposomal PC (Supplemental
Fig. S1). A liposomal marker solutionwas used in each series of animals.
Photodecay was determined by comparing the normalized marker in-
tensities of the ﬁrst two measurements (1.02 ± 0.05) and the last two
measurements (0.98 ± 0.03), corresponding to a loss of signal of
~3.5% (p = 0.01 in a paired t-test). DiR's photodecay was thus very
low over the entire measurement period. Since the TRE measured
were normalized to marker intensities, TRE were corrected for respec-
tive photodecay.
3.4. Accumulation kinetics of liposomes in tumor-bearing rats
The accumulation of long circulating liposomes in tumor, skin, paws,
and ears was followed by in vivo ﬂuorescence imaging over a period
lasting up to 7 days. Respective ROIs of 1.5 cm diameter for skin and
tumor and 0.5 cmdiameter for paws and ears were deﬁned and ﬂuores-
cence intensity quantiﬁed within. A typical example is shown in Fig. 3,
detailed data for each measurement are given in the Supplement 2.
The ﬂuorescence average recorded for the different regions is illustrated
in Fig. 4, where mean and s.d. are given. Normality of data distribution
was tested by Shapiro-Wilk criteria (p N 0.05), revealing normality for
all data except the paws' lowest values in the plasmapheresis group,
whichwere close to tissue auto ﬂuorescence level. Since we used a sub-
cutaneous tumor model, the ﬂuorescence recorded in the tumor ROI
consists of tumor ﬂuorescence and skin ﬂuorescence. Thus the TRE of
skin recorded elsewhere was subtracted from the TRE in the tumor
ROI. Tumor tissue accumulates nanoparticles by means of EPR, and not
surprisingly, the ﬂuorescence signal in tumor increases with time,
0.5 h 2 h 6 h 12 h
22 h 24 h 34 h 50 h
69 h 93 h 174 h
* *
* *
*
*
Fig. 3. In-vivo-ﬂuorescence measurement of liposomal biodistribution. DiR-labeled liposomes were injected into the tail vein of tumor-bearing female Fisher rats to an initial blood
concentration of ~4 mM liposomal PC. The left animal received plasmapheresis after 22 h, indicated by an asterisk. The arbitrary color scale is reaching from 9.4 E8 to 8.4 E9 [(p/s/
cm2/sr)/(μW/cm2)]. A typical example is shown (n= 8–9), detailed data and all ROI chosen are given in Supplement 2.
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the falling blood concentration.
Measured TRE are composed of tissue auto ﬂuorescence, signal de-
rived from respective tissue (Ftissue) and signal from blood within that
tissue (Fblood). Tissue autoﬂuorescencewas recorded prior to the liposo-
mal injection, accounting for an average TRE = 1.4 E8 (ear), 2.8 E8
(paw), 1.4 E9 (skin) and 1.8 E9 (tumor). To calculate the tissue signal,
tissue auto ﬂuorescence and Fblood must be subtracted from measured
TRE. To account for the decrease in Fblood over time, TRE obtained imme-
diately after an infusion (t=15–30min) was assumed to be only relat-
ed to the ﬂuorescence in blood, since virtually no accumulation had
occurred yet. A decrease in respective blood signal intensity was calcu-
lated with ﬁrst order kinetics and a plasma T½ of 29 h as measured for
the liposomes used (see Fig. 1A). Accumulation of liposomes in tumor
can best be described as fast exponential accumulation and slow linear
decay (Fig. 5A). Since decay is very slow, the kinetic order of decay could
not be evaluated within the observation period, but taking the simplest
approach of zero order linear decay enabled sufﬁcient data ﬁtting. Accu-
mulation in tumor reached a plateau phase with little
change between ~48 and 96 h, revealing a maximum of ~4.1 RFU at
about 60 h. The accumulation in skin was much lower than in tumor,
which exhibited amaximum of ~0.72 RFU at ~80 h (Fig. 5B). Accumula-
tion half-times were 21 h and 30 h, respectively. Fluorescence decay in
skin was less than in tumor (Dskin = 0.003 RFU/h and Dtumor = 0.006
RFU/h), but regarding the total accumulated ﬂuorescence, it was pro-
portionately faster in skin. Fpaw (Fig. 5C) and Fear (Fig. 5D) were much
lower than Fskin, with a maximum at ~0.072 RFU and ~0.016 RFU, re-
spectively. Considering that the ROI in paws and ears measured
0.79 cm2 and ROI in skin (and tumor) 7.1 cm2, the Fmax in paws isapprox. the same as that in skin. Accumulation half-time recorded for
paws was 51 h, in ear 54 h. We documented no decay within the ob-
served time frame in paws and ears, probably because it remained
below the detection level.
3.5. Inﬂuence of plasmapheresis on accumulation
To study the effect of plasmapheresis on accumulation, a signiﬁcant
amount of liposomes must be present in the plasma. Plasmapheresis
was therefore performed between 22 h and 24 h after liposome injec-
tion, when ~60% of the initial dose are still circulating, even though
the accumulation of liposomes in tumor has not reached its plateau
phase yet. A typical example of ﬂuorescence intensity evolution when
conducting plasmapheresis is shown in Fig. 3 (left animal), for detailed
data on each animal see Supplement 2. Average TREs are given in Fig. 4
and Ftissue calculated for the plasmapheresis group are shown in Fig. 6.
We noted a signiﬁcant drop in TRE in skin, paws, and ears, where Fblood
is predominant, but only a small drop in TRE in tumor during plasma-
pheresis. Average efﬁciency of plasmapheresis in tumor-bearing rats
was 38%. (±7%). The decline in TRE observed during plasmapheresis
accounted for 16% (tumor), 33% (skin), 33% (paws) and 44% (ears) of
the respective Fblood. Since the observed decline was smaller or within
the range of plasmapheresis efﬁciency, we attributed the decrease in
TRE to a drop in Fblood only, while Ftissue remained unaffected. Tumor tis-
sue attained maximum accumulation at ~4.3 RFU, showing an accumu-
lation half-time of 16 h. Decay observed for tumor was 0.013 RFU/h. In
contrast, we observed a signiﬁcant loss of ﬂuorescence intensity in
skin and paws after plasmapheresis. Thus a single function was unable
to describe the accumulation-time curve adequately. To calculate
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Fig. 4. Evolution of ﬂuorescence intensities. DiR-labeled liposomes were injected into the tail vein of tumor-bearing rats to an initial blood concentration of ~4 mM liposomal PC. ROIs for
tumor and skin (15 mm diameter), ears and paws (5 mm diameter) were chosen, and ﬂuorescence intensity (TRE, total radiant efﬁciency) was measured within these ROIs. Mean
ﬂuorescence intensities and s.d. are given. Plasmapheresis was performed after 22 h. Tissue auto ﬂuorescence is given as orange line. A) Tumor; B) skin; C) paws; D) ears; red control,
blue plasmapheresis group; signiﬁcant differences are indicated by asterisks (*** p b 0.01; ** 0.01 b p N 0.05 and * 0.05 b p N 0.1).
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and 49 h were neglected and the data ﬁtted by exponential accumula-
tion and linear decay as described (dotted line in Fig. 7), thereby calcu-
lating Fmax to 0.37 RFU for skin and 0.019 RFU for paws. Accumulation
in ears was close to tissue auto ﬂuorescence and exhibited minimal to
no accumulation.
The accumulation in the animals undergoing plasmapheresis is com-
pared to control animals in Fig. 7. Averages of tissue accumulation and
95%-CI are given, since CI describe the probability distribution of calcu-
lated averages better than s.d. Averageswere used to calculate the accu-
mulation time curve. Finally, calculated ﬁts for the accumulation time-
curve were tested by the extra-sum-of-squares F test to justify the use
of two different ﬁts for control and plasmapheresis animals instead of
a single ﬁt (null hypothesis). p–values for the extra-sum-of-squares F
test were below 0.01 for skin, paws and ears, while we detected no dif-
ference in tumor (p≫ 0.1) despite differences in decay. The accumula-
tion phase in tumor (up to 48 h) is not affected by plasmapheresis, and
Fmax does not differ betweenplasmapheresis and control groups. In con-
trast to tumor, Fmax in other tissues was signiﬁcantly decreased in the
plasmapheresis group post-plasmapheresis. Accumulation until plas-
mapheresis in skin and paws was quite similar in the control and
plasmapheresis groups (except the skin value for 22 h that is slightly
lower in the plasmapheresis group, although the difference is not
signiﬁcant after t-testing). After plasmapheresis, a signiﬁcant loss ofaccumulated ﬂuorescence is observed in skin and paws, followed by
slow accumulation afterwards. Accumulation time curves are signiﬁ-
cantly different even when disregarding the time points between
32 h–50 h. Consequently, the accumulation half-time was reduced in
the plasmapheresis group. In ears, accumulation was signiﬁcant lower
in the ears of the animals undergoing plasmapheresis as well, even
though low signal intensities led to wide variance and interpretations
should be made with caution.
3.6. Dose dependency of accumulation
When concentrations of 2 to 6 mM liposomal PC were given to the
animals, we observed similar accumulation kinetics, with tumor
Amax = 2.1 (1.1–3.0); 4.6 (3.3–6.0) and 6.5 (5.1–7.9) for 2, 4 and
6 mM liposomal PC, respectively (see Supplemental Fig. S2). Thus the
accumulation of DiR-marked pegylated liposomes in the observed con-
centration range correlates approximately linearly to the liposomal
plasma concentration.
3.7. Tissue ﬂuorescence ex vivo
Rats were sacriﬁced 48 h after plasmapheresis. Tumor, skin, paws
and ears, as well as the liver and spleen were excised and subjected to
optical imaging. Averages and s.d., normalized to marker intensity, are
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Fig. 5.Accumulation of liposomes in control animals.Mean and s.d. of total radiant efﬁciency (TRE)were recorded as described in Fig. 4. (n=9). Tissue autoﬂuorescence and the calculated
ﬂuorescence of liposomes in the blood vessels of the given tissues (pink dotted line) was subtracted from TRE (red symbols and dashed line) to yield the ﬂuorescence of liposomes
accumulating in the tissue of interest (black symbols and solid line). Blood ﬂuorescence was assumed to correspond to initial signal (t= 15–30 min) and was calculated according to
measured half-life (Fig. 1A). A) Tumor; B) skin; C) paws and D) ears.
64 R. Ngoune et al. / Journal of Controlled Release 238 (2016) 58–70given in Fig. 8, tissues are shown in Supplemental Fig. S3. We observed
nodifferences in ﬂuorescence intensity in the spleen,while the liver and
lung demonstrated signiﬁcant less ﬂuorescence intensity in the plasma-
pheresis group. As observed with accumulation kinetics, skin, paws and
ears revealed less ﬂuorescence in the animals receiving plasmapheresis,
but these differences were not statistically signiﬁcant due to wide vari-
ation. Tumor showed slightly less ﬂuorescence in the plasmapheresis
group too, but the differences were insigniﬁcant (p≫ 0.1).
Accumulation of liposomes in investigated tissues was conﬁrmed by
ﬂuorescencemicroscopy (Fig. 9). As expected for organs of themononu-
clear phagocyte system (MPS), spleen and liver macrophages accumu-
late high amounts of liposomes as do lung macrophages. Not
surprisingly ﬂuorescence in spleen is much more intense than in other
organs. Fluorescence in tumor is unevenly distributed, as described by
[6,24] and many others. It is less intense than ﬂuorescence in MPS, but
higher than ﬂuorescence in skin and ears, as expected. Minimal ﬂuores-
cence in ears can be detected, presumably located to the dermal section.
Tissue slices of paws could not be prepared.
4. Discussion
The aim of this research was to investigate the hypothesis of unidi-
rectional accumulation of liposomes via EPR in tumor tissue, in contrast
to the accumulation in other tissueswhere diffusion equilibriummay be
present.4.1. Liposomes
For these experiments we used pegylated liposomes to achieve a
sufﬁcient plasma-half-life to study EPR. Liposomes were composed of
cholesterol and HSPC as commercial PLD, except for increasing the
amount of PEG to 10 mol%. The average plasma half-life observed was
~29 h, in accordance with ample data in the literature on pegylated li-
posomeswithout cargo. The observed half-life iswell suited for examin-
ing EPR.
To maximize the ﬂuorescence signal, a high concentration of lipo-
somes might be useful. Furthermore, plasma T½ was slightly dose-de-
pendent, favoring high concentrations as well. On the other hand, a
saturation of ﬂuorescence or accumulation processes has to be ruled
out. The accumulation in tumor tissues was ~linear up to 6 mM liposo-
mal PC, thus we chose a concentration of 4 mM liposomal PC for the ex-
periments. Clinically-applicable pegylated liposomal doxorubicin is
used at much lower concentrations (~0.2 mM) [17]. Nevertheless, the
accumulationmaximum in tumors of liposomes is reported to correlate
linearly to the plasma concentration over a wide range of concentra-
tions (e.g., [8,9]), and the principles of accumulation should be similar
for different concentrations.
Hagtvet et al. [19] concluded that in vivo imaging may be useful to
study biodistribution in tumors, but a stable association between
markers and liposomes is crucial. Hagtvet et al. modiﬁed PLD with
carbocyanine dye DiD after preparing liposomes, and observed an
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Fig. 6.Accumulation of liposomes in plasmapheresis group. Plasmapheresis was performed 22 h post liposome injection (n=8).Measured TRE are given in dark blue (dashed lines) and
calculated accumulation is given in sky blue (solid line). For further details see Fig. 5.
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proteins. In contrast, we added the ﬂuorescence dye while preparing
the liposomes. Since no transfer of ﬂuorescence from liposomes to lipo-
proteins or plasma proteins appeared in GPC analysis, the dye was sta-
bly incorporated within the liposomes used. The chemical structure of
the DiR we used here and that of the DiD used by Hagtvet et al. is nearly
identical. Probably, the dye is completely incorporated into the mem-
brane when present during membrane formation, while post-prepara-
tion modiﬁcation may lead to a certain amount of weakly associated
dye.
4.2. In vivo ﬂuorescence imaging
In vivo ﬂuorescence imaging allows for non-invasive observation of
biodistribution data in a single animal over a prolonged period. The near
infrared ﬂuorescent dye DiR revealed the lowest intrinsic ﬂuorescence
of the carbocyanine dyes we investigated, and the accumulation signals
were much higher than tissue auto ﬂuorescence except in paws and
ears in the plasmapheresis group, which did not exhibit elevated accu-
mulation (Fig. 4). Photodecay accounted for only ~3.5% loss of signal
over the measurement period, which was corrected by normalization
by marker intensities. Photodecay in tissue might be different from
photodecay in marker solution, but is expected to be rather less than
that observed for marker solution, since destructive light energy in
tissue might be absorbed by other molecules as well. Self-quenched ac-
cumulated ﬂuorescence may be another problem. We veriﬁed thelinearity of ﬂuorescence intensities in the detection range via a series
of different concentrations that displayed good linearity over the full ob-
servation range. When 2 to 6mM liposomal PC were used, the accumu-
lation was ~linearly correlated to liposomal concentration. Thus the
respective ﬂuorescence signal for 4 mM is not hampered by self-
quenching.
Following the time course of biodistribution in a batch of animals
greatly reduces the number of animals needed, thereby eliminating
inter-individual variations between time points. On the other hand, op-
tical imaging only enables two-dimensional images, and the light pene-
tration into the animal is limited. The animals' surface tissues like skin,
paws, and earswere easily accessible, aswere the subcutaneous tumors.
We thus chose a subcutaneous tumor model.
With rats as our animalmodel, the limited penetration depth of near
infrared optical imaging did not permit us to observe deeper organs like
the liver and spleen. To monitor those organs, rats were sacriﬁced after
48 h and their organs measured ex vivo (Fig. 8). Skin and paws are
mayor sites of adverse effects of PLD and were easily measured by opti-
cal imaging. Ears aremainly composed of cartilage andwere intended as
negative control. Nevertheless, minimal accumulation was detectable
by the methods we used as well, presumably in the dermal section.
While tissues can be perfused invasively prior to preparation, optical
imaging cannot distinguish between the tissue signal and the signal de-
rived from the blood pool within the given tissue. To assess the blood
signal in question, we used the measured half-life of marked liposomes
to calculate the blood signal from the initial signal recorded. By
0 24 48 72 96 120 144
0
1
2
3
4
5
time [h]
in
te
ns
ity
10
10
control
plasmapheresis
A tumor
0 24 48 72 96 120 144
0.0
0.2
0.4
0.6
0.8
1.0
time [h]
in
te
ns
ity
10
10
plasmapheresis
controlB skin
**
*
*
*
**
**
** **
0 24 48 72 96 120 144
0.00
0.05
0.10
time [h]
in
te
n
s
ity
10
10
control
plasmapheresis
*
**
**
**
***
***
C paws
0 24 48 72 96 120 144
0.00
0.01
0.02
0.03
0.04
time [h]
in
te
ns
ity
10
10
*
**
**
D ears
plasmapheresis
control
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nal recorded,we obtained good accumulation data for the tissueswe ex-
amined - even for the ears, where accumulation is very low.
One bias of the method we used is the scattering of TRE and subse-
quent accumulation data.Mayor sources of variance in tissue accumula-
tion are differences in biology between different animals, which cannot
be eliminated. Furthermore, in vivo ﬂuorescence is a semiquantitative
method that addsmethodological variance. How the animals are placed,
and the choice of ROI greatly inﬂuence measurements and are not pre-
cisely reproducible. The signal depends on tissue penetration, which
also differs in various tissues. In tumor, the penetration depth may
change in conjunctionwith tumor growthor changes in tumor structure
like development of a necrotic core. Furthermore, differences in liposo-
mal preparations inﬂuence the plasma half-life and ﬂuorescence signal
intensities. On the other hand, longitudinal differences between animals
sacriﬁced at different time points are eliminated by the continuous non-
invasive observation of tissue ﬂuorescence in the same group of ani-
mals. Despite obvious scattering of the data, TRE measured in skin and
paws differed signiﬁcantly between the control and plasmapheresis
groups, and in vivo ﬂuorescence enables the detailed observation and
comparison of accumulation kinetics when sufﬁcient animals are used.
4.3. Accumulation of liposomes
MAT-B-III rat tumormodels have been used to address tumor vascu-
larity and hemodynamics via different imaging approaches [25–27]. TheMAT-B-III model is characterized by hypervascularization, that is also a
feature of certain human tumors like liver metastases [25,26]. Mat-B-III
tumors reveal a high degree of necrosis, mainly in the tumor core, as
seen inmany human tumors aswell [26]. Mat-B-III tumors differ widely
in their VEGF-expression, consequently different angiogenetic activity,
that correlates to EPR activity and tumor aggressivity [27]. The varia-
tions observed in tumor accumulation may be at least in part attribut-
able to the known wide variation in angiogenetic activity. As that
differs widely in human tumors as well [28], as does the EPR-based ac-
cumulation of nanoparticles [9,29], the MAT-B-III model we used may
reﬂect at least part of these differences. Even though EPR is a basic prin-
ciple, its heterogeneity in human tumors is a major drawback to the
clinical success of macromolecular drugs and delivery systems; and in-
novative approaches are needed to overcome this drawback [30].
Due to the large plateau phase between ~48 and 96 h, precise esti-
mations of the accumulationmaximumwas difﬁcult. Themaximum ac-
cumulation of liposomes in tumor tissue was observed at ~60 h. This
ﬁnding concurs with previous data obtained by optical imaging [19] or
radio labelling [31]. Other working groups identiﬁed accumulation
maximums at ~24 h [8,12,18]. The latter projects applied an orthotropic
tumor model, while we used an s.c. tumor model for imaging reasons.
Orthotropic models are known to reveal more pronounced EPR [32],
probably triggering faster accumulation. Besides artiﬁcial xenograft
tumor models, EPR-based drug targeting has been successfully
attempted in carcinogen-induced tumor models as well [20], probably
reﬂecting the human situation better. While animal tumors may grow
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Fig. 8. Organ distribution 48 h after liposome injection. About 48 h after injection of
ﬂuorescent liposomes (4 mM liposomal PC) animals were sacriﬁced (n = 4–5).
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67R. Ngoune et al. / Journal of Controlled Release 238 (2016) 58–70within weeks to provide a useful model, human tumors grow over
much longer time spans and often exhibit signiﬁcant intratumoral het-
erogeneity with respect to genetic and physiologic alterations [33] that
cannot be observed in a fast growing animal model.
Unlikewith the total amount of accumulation, accumulation kinetics
did not vary between liposomes of different sizes [18]. Interestingly, the
same tumor model exhibited maximum tumor accumulation at 24 h
when using non-pegylated liposomes [18] or PLD [8], implying that
the prolonged half-life of PLD does not lead to an extended accumula-
tion period. Taken together, liposome characteristics are probably less
important for the shape of the accumulation-time curve than are the
tumor's intrinsic properties.
4.4. Accumulation and plasmapheresis
A syngeneic rat model was used in this study to avoid immune-sup-
pressed animals since plasmapheresis was not performed in a sterileenvironment. We opted for rats because the blood volume in mice is
too small to allow plasmapheresis. Folette et al. demonstrated that plas-
mapheresis in rats is feasible [34]. However, the animals in their study
had permanent catheter access to the jugular and femoral vein regions
and required elaborate surgery. To spare the tumor-bearing animals ad-
ditional discomfort, we decided against permanent access and instead
for minimally-invasive temporal access to the tail vein. Double ﬁltration
plasmapheresis demands precise control of transmembrane pressure,
which is difﬁcult to achieve in miniaturized experimental systems.
Thus we introduced a simple discontinuous technique that proved to
be nearly as effective as the highly sophisticated plasmapheresis equip-
ment used in clinical settings [17].
In a therapeutic setting, plasmapheresis should take place when the
tumor accumulation has reached its plateau phase. On the other hand,
to study the effect of plasmapheresis on accumulation, a signiﬁcant
amount of liposomesmust be present in the plasma. The liposomes pre-
pared for this study had a plasma half-life of ~29 h.When accumulation
reaches the plateau phase after ~48 h, only ~32% of the initial dose
would be present in plasma, and plasmapheresis effects would be min-
imal. Thus plasmapheresis was conducted when ~60% of initial dose
were still present in plasma (between 22 h and 24 h after liposome in-
jection), even though the accumulation of liposomes in tumor had not
yet reached its maximum.
Plasmapheresis leads to a signiﬁcant drop in TRE in skin, paws, and
ears, attributed to the elimination of liposomes in blood. Further lipo-
some accumulation in these tissues is signiﬁcantly hampered after plas-
mapheresis. This would be expected of a classical diffusion-driven
accumulationmechanism,where the accumulating compartment exists
in free exchange with plasma compartment. Furthermore, notable
drops in Fskin and Fpaws are observed after plasmapheresis (Fig. 7B and
C), with signiﬁcant differences (p N 0.05) observed for skin when t-test-
ing 22 h against 42 and 49 h. These drops are possible due to the net
loss of already accumulated liposomes due to a disturbance in balance
between liposomes entering and leaving the given tissues in the classic
diffusion-driven model. Whether liposomes already accumulated leave
certain tissues cannot be veriﬁed by themethods used.While ﬁtting the
accumulation kinetics of control animals via a typical exponential equi-
tation, ﬁtting accumulation kinetics for the plasmapheresis group's skin
and paws was difﬁcult. Using a single function leads to a ﬁtting bias
prior to plasmapheresis, since lower values post-plasmapheresis distort
the function to minimize error sum. A more accurate ﬁt would demand
three different functions: one prior to plasmapheresis, a second describ-
ing the drop immediately post-plasmapheresis, and a third describing
long term accumulation. Regarding the number ofmeasured data points
and respective variations, the ﬁtting of three functions cannot be justi-
ﬁed, and the accumulation in skin and paws was ﬁtted neglecting the
data points immediately after plasmapheresis via the exponential equa-
tion used for control animals as well, despite a signiﬁcant methodolog-
ical bias. Nevertheless, accumulation ebbs away after plasmapheresis,
leading to a signiﬁcantly lower amount of liposomes in skin and paws,
than that observed in control animals.
Plasmapheresis failed to lead to a difference in the accumulation
maximum in tumor tissue, as it did in the other tissues. We observed
only a small drop in total ﬂuorescence in conjunction with plasmaphe-
resis, accounting for ~16% of Fblood. Accumulation in tumor is very fast,
especially within the ﬁrst hours, and the proportion of Fblood may be
somewhat overestimated by the assumption that Fblood(0) corresponds
to Ftotal measured 15–30 min after the injection. Furthermore, tumors
growing subcutaneously can modify the skin above. As dermatological
irregularities probably trigger less skin-derived ﬂuorescence, we possi-
bly subtracted more skin derived ﬂuorescence than appropriate when
calculating Ftumor. Hence the drop in TRE was over-allocated to the
skin. Furthermore, tumor accumulation may be overestimated when
certain regions in tumor vessels are not perfused for a certain period
[35]. Liposomes trapped in these vessels are not susceptible to plasma-
pheresis, but add to the TRE recorded after plasmapheresis. Once these
control plasmapheresis
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Fig. 9. Fluorescence microscopy of tissues 48 h after liposome injection. Tissues (see Fig. 8) were sliced and subjected to ﬂuorescence microscopy (exc./em. 555/577–602 nm). Left panel:
phase contrast, right panel ﬂuorescence (recording time 2000 ms, except for spleen, 500 ms). A) Liver; B) spleen; C lung; D) tumor; E) skin; F) ear. Typical examples are shown.
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should drop more rapidly than in the control group, as we observed.
We could not investigate the internal organs by in vivo ﬂuorescence
in the animalmodelwe used. Therefore a small number of animalswere
sacriﬁced 48 h after liposome injection (~24 h post plasmapheresis).
While the spleen presented no differences, the plasmapheresis group's
liver and lung revealed signiﬁcantly less ﬂuorescence. All three organs
contain signiﬁcant amounts of macrophages known to take up lipo-
somes even when pegylated. In contrast to the accumulation kinetics
shown in Fig. 7, ex vivo tissue ﬂuorescence corresponds to Ftissue and re-
sidual Fblood, respectively, corresponding to TRE data. Thus total organ
ﬂuorescence must be interpreted with caution. The tumor signal was
slightly weaker in the plasmapheresis group, as apparent with TRE as
well (see Fig. 4A) In line with in vivo ﬂuorescence data, the skin,
paws, and ears showed a tendency to less ﬂuorescence in theplasmapheresis group, butwenotednoobvious signiﬁcance by t-testing
due to wide variations.
4.5. Clinical implications
In an initial clinical study, double ﬁltration plasmapheresis of PLD
proved to eliminate PLD from patients' blood very effectively, and
even a high-dose protocol revealed a very mild adverse event proﬁle
[17]. Despite theoretical considerations, the fear remained of reducing
anticancer efﬁcacy due to a loss of accumulated liposomes. We demon-
strate here that there is no loss of accumulated liposomes when the
blood concentration drops rapidly due to plasmapheresis. We observed
no difference in maximum accumulations, but only a slightly accelerat-
ed decay of ﬂuorescence in tumor. Whether this slight decrease in AUC
of liposomes in tumormaybe clinically relevantwhen applying PLD and
69R. Ngoune et al. / Journal of Controlled Release 238 (2016) 58–70plasmapheresis after 48h, cannot be deduced from thiswork.Neverthe-
less a slight long termdecrease in liposomesmaybe easily compensated
via a higher dose enabled by reduced toxicity. Unlike in tumor, we ob-
served signiﬁcantly fewer liposomes in skin and paws and even in
ears in the plasmapheresis group, which explains the diminished rates
of skin toxicity observed in the clinical setting. We believe our results
encourage the further development of plasmapheresis in anticancer
therapy using long circulating nanoparticles like PLD.4.6. EPR
EPR is the key accumulation mechanism in tumor tissue for a wide
variety of nanoparticles [2]. For one, EPR allows a certain intrinsic
tumor-speciﬁc accumulation of nanoparticles, but it remains the bottle-
neck throughwhichmore advanced nano-targeting therapiesmust pass
[36].Within the ﬁrst hours after liposomes are injected, their accumula-
tion in tumor is very rapid. Already ~82% of total accumulation had oc-
curred after a single half-life (29 h). Why the remaining 50% of
circulating liposomes did not adequately accumulate is not yet known.
The data we obtained via plasmapheresis reveals unidirectional accu-
mulation and virtually no diffusion of nanoparticles from tumor to plas-
ma. A saturation effect in tumor tissue due to limited binding sites can
be ruled out since higher plasma concentrations are directly related to
higher amounts of accumulated liposomes. Accumulation of liposomes
in tumor is much faster than respective elimination from tumor, thus
accumulation should proceed according to the plasma half-life, as we
observed in the skin and ears. One approach to interpreting the ham-
pered accumulation is a “clogged pore model”, where gaps in the endo-
thelial layer are blocked by particles that become entangled within the
pore, e.g., by matrix elements or by interaction with hemostatic active
components, thus preventing further accumulation. With many pores
blocked after a while, the accumulation kinetic drops sharply, even
though the diffusion potential would still allow further accumulation.
Of course, blocked pores hinder the loss of liposomes once plasmaphe-
resis has lowered the plasma concentration. Clogged pores may slowly
reopen after several hours, allowing accumulation to proceed, but
since the blood concentration is low at this time, further accumulation
is also low.
Sometimes a certain “reload”-mechanism is discussed in conjunc-
tion with long circulating liposomes. Since the accumulation maximum
cannot be attributed to saturation, a reload of catabolized liposomes is
not likely. More likely, accumulation continues when new or blocked
dynamic pores reopen after a while, even though further accumulation
is low due to low plasma concentration. Net accumulation at low plas-
ma concentrations can only occurwhen no back diffusion of extravasat-
ed liposomes takes place, as suggested by the present plasmapheresis
data as well as earlier data based on pharmacokinetic considerations
[11].
Both physically entangled liposomes and gaps in the endothelial
layer can change. Endothelial cells in tumor are dynamic, and there is
evidence that they change their position, shape, and size. Stirland et al.
very recently reported that silica nanoparticles display a substantially
different distribution pattern when administered consecutively over
several hours [37]. The temporary appearance of large gaps in tumor en-
dothelia was discovered via intravital microscopy leading to “vascular
bursts” that presumably add to the accumulation of nanoparticles in tu-
mors [38]. Tumor blood vessels are dynamic in their structure and func-
tion, and uptake of macromolecules and nanoparticles can be easily
modiﬁed by vasoactive substances [2,24,39]. Taken together, the gaps
in leaky endothelia are more likely to be a rather dynamic feature
than a static construct. Cells in the endothelial layer react to external
stimuli and perhaps also to stimuli from intrinsic blood ﬂow dynamics.
Theymay react to stimuli originating fromaccumulatingparticles them-
selves as well, and the nature of the nanoparticles used may inﬂuence
EPR properties too.Despite intrinsic passive targeting to tumor tissue and signiﬁcant en-
hanced accumulation in tumors, very few nanoparticle-based drugs
have entered clinical practice [40] today. Mechanisms of nanoparticle
accumulation are more complex than a simple escape mechanism
through large gaps. Since many if not all nanoparticle-based drug deliv-
ery systems addressing tumor cells rely on the EPR, a deeper under-
standing of this accumulation mechanism is urgently needed and
could lead to signiﬁcantly more effective drug delivery in anticancer
therapy.
Supplementary data to this article can be found online at http://dx.
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